test results, page-2

Hi Spalding,

I'm finally back from my holiday and back to research.

This announcement doesn't contain any new information and I believe that's the reason the announcement wasn't made price sensitive.

However it does show that the scientific community is excited about Phenoxodiol, perhaps much more so than investors are. Phenoxodiol is slowely becoming better known and it's not long now before we see some preliminary Phase II results (that's what the big insto's are interested in).

In my opinion the skin cancer trial is likely to accelerate FDA approval for Phenoxodiol. The pilot trial saw some quite incredible results and hopefully they can repeat them in the Phase II trial underway.

Another item to watch for that is probably worth more than the current share price alone is NV-07a. They are very close to commercialisation and signing a deal with a large cosmetic company. It's a breakthrough in skin care and could become as big as sun screens. My guess at a E(NPV) is a minimum of $6 per share and the upside is massive.

So rest easy if your a NRT holder... no need to panic any more as the chance of FDA approval and NV-07a commercialisation is very high (in my opinion). Personally I'm 100% sure of making a killing on Novogen over the next 6-12 months.

Cheers,
Munch.